Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages.
Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages.
复制标题
DOI：
10.1016/j.talanta.2020.121898
复制
发表时间：
2021-04-01
期刊：
影响因子：
6.1
通讯作者：
Mir M
中科院分区：
文献类型：
--
作者：
Pérez-López B;Mir M
当前新冠肺炎大流行的特点是感染人数多、致死率高、传播迅速。这些情况使几乎整个世界的活动都停止了，严重影响了全球经济。快速诊断Covid-19和通用检测方案对于抗击大流行和维持人群健康控制至关重要。用于监测SARS-CoV-2传播的主要生物传感和诊断技术是基于特定的基因组分析和快速免疫测试，两者具有不同的技术平台，其中包括优点和缺点。大多数体外诊断企业为了尽快将新冠病毒检测平台投放到这个巨大的国际市场，都在竞相根据不同的法规率先验证自己的技术。本文综合分析了用于Covid-19诊断的基因组传感和抗体/抗原检测方法的商业化技术，并根据不同国家的法规详细列出了这些技术。讨论了所述技术在该疾病不同阶段的有效性，并对市场上用于应对这一流行病的新兴技术进行了重要比较。
The current situation of the Covid-19 pandemic is indicated by a huge number of infections, high lethality, and rapid spread. These circumstances have stopped the activity of almost the entire world, affecting severely the global economy. A rapid diagnosis of the Covid-19 and a generalized testing protocol is essential to fight against the pandemic and to maintain health control in the population. Principal biosensing and diagnostic technologies used to monitor the spread of the SARS-CoV-2 are based on specific genomic analysis and rapid immune tests, both with different technology platforms that include advantages and disadvantages. Most of the in vitro diagnosis companies are competing to be the first on validating under different regulations their technology for placing their platforms for Covid-19 detection as fast as possible in this big international market. A comprehensive analysis of the commercialized technologies for the genomic based sensing and the antibody/antigen detection methods devoted to Covid-19 diagnosis is described in this review, which have been detailed and listed under different countries regulations. The effectiveness of the described technologies throughout the different stages of the disease and a critical comparison of the emerging technologies in the market to counterattack this pandemic have been discussed.
登录
查看更多内容
影响因子：
82.9
作者：
Amanat F;Stadlbauer D;Strohmeier S;Nguyen THO;Chromikova V;McMahon M;Jiang K;Arunkumar GA;Jurczyszak D;Polanco J;Bermudez-Gonzalez M;Kleiner G;Aydillo T;Miorin L;Fierer DS;Lugo LA;Kojic EM;Stoever J;Liu STH;Cunningham-Rundles C;Felgner PL;Moran T;García-Sastre A;Caplivski D;Cheng AC;Kedzierska K;Vapalahti O;Hepojoki JM;Simon V;Krammer F
通讯作者：
Krammer F
影响因子：
4.1
作者：
Chau, Cindy H.;Strope, Jonathan D.;Figg, William D.
通讯作者：
Figg, William D.
影响因子：
64.8
作者：
Bao, Linlin;Deng, Wei;Qin, Chuan
通讯作者：
Qin, Chuan
影响因子：
19
作者：
Corman, Victor M.;Landt, Olfert;Drosten, Christian
通讯作者：
Drosten, Christian